Loading…
Employees: 186
Size Pharmicell (005690.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $352M, the 428th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩7,960 on 6 Nov 2026.
Performance Over six months the shares fell 56.0%, against -22.5% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 19 in its peer set.
Growth Revenue grew 51.3% over the last twelve months (peer median -1.2%); the operating margin is 32.1% (peer median -42.4%).
Valuation It trades at 8.1× forward earnings against a peer median of 35.3× (cheapest of 4).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is -31 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 24.5 points above its cost of capital (6.6% WACC).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩136B | ₩114B | ₩64.9B | ₩56.2B | ₩60.2B |
| Revenue growth | — | +76% | +15% | -7% | — |
| Gross profit | ₩59.8B | ₩50.0B | ₩20.6B | ₩15.0B | ₩23.3B |
| EBITDA | ₩46.6B | ₩36.8B | ₩7.24B | ₩3.79B | ₩10.3B |
| Net income | ₩46.5B | ₩40.3B | ₩6.33B | ₩3.58B | ₩8.26B |
| Free cash flow | ₩26.1B | ₩33.6B | -₩780M | ₩5.80B | -₩11.0B |
| Capital expenditure | ₩14.9B | ₩7.49B | ₩4.34B | ₩6.02B | ₩19.0B |
| Total debt | ₩25.5B | ₩14.6B | ₩686M | ₩3.03B | ₩16.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 005690.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -38.9% | -9.9% | 2nd lowest of 20 |
| 6-month return | -56.0% | -22.5% | 2nd lowest of 19 |
| Distance from 52-week high | -62.4% | -33.3% | 5th lowest of 21 |
| Revenue growth (TTM) | +51.3% | -1.2% | 4th highest of 19 |
| Operating margin | 32.1% | -42.4% | 2nd highest of 17 |
| Forward P/E | 8.1× | 35.3× | cheapest of 4 |
| Growth the price implies (Req g, 7 yrs) | -6.6% | 14.8% | least demanding of 7 |
| Growth delivered (Del g) | +24.8% | -1.7% | highest of 7 |
| Hurdle (Req g minus delivered) | -31.4 pp | +18.5 pp | least demanding of 7 |
| ROIC minus cost of capital | +24.5 pp | -16.4 pp | 2nd highest of 16 |
| EV / EBITDA | 9.4× | 15.4× | 2nd cheapest of 4 |
| Net debt / EBITDA | -0.9× | 0.9× | least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 8.1× | -6.6% | +24.8% |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | n/a | n/a | n/a |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | n/a | n/a | n/a |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | n/a | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 295.1× | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | 12.3× | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 35.3× | 10.5% | +4.2% |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | n/a | n/a | n/a |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | n/a | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | n/a | 13.2% | +6.5% |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | n/a | 28.5% | -6.4% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | n/a | n/a | n/a |
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | n/a | 4.2% | +3.1% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | n/a | 16.3% | -14.0% |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | n/a | n/a | n/a |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | n/a | 58.0% | -12.8% |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |